跳至主要内容
临床试验/NCT00064467
NCT00064467已完成3 期

An 8 Week, Multicenter, Randomized, Double-blind, Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms

GlaxoSmithKline25 个研究点 分布在 1 个国家目标入组 268 人开始时间: 2003年6月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
268
试验地点
25
主要终点
Change from randomization on the Inventory of Depressive Symptomatology, self report and clinician rated.

研究概览

简要总结

This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.

详细描述

A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Change from randomization on the Inventory of Depressive Symptomatology, self report and clinician rated.

次要结局

  • Percent of responders. Percent of remitters. Quality of Life Enjoyment and Satisfaction Questionnaire.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (25)

Loading locations...

相似试验